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2. SUMMARY  
 
Protein tyrosine phosphatase 1B (PTP1B) is a member of the classical tyrosine 
phosphatase family, which modulates diverse biological processes including 
proliferation, differentiation, apoptosis and migration. PTP1B is a major regulator of 
cell metabolism. It decreases insulin signaling by dephosphorylating the insulin 
receptor and IRS proteins, and attenuates leptin action by dephosphorylating JAK2. 
Identifying PTP1B as an important target in diabetes and obesity. PTP1B has received 
additional attention because several studies revealed a role for PTP1B in different 
types of cancer, including breast neoplasia. PTP1B is overexpressed in human breast 
cancer, and depletion of PTP1B delays mammary tumorigenesis in mouse models of 
mammary cancer induced by activated ERBB2. However, relatively little was known 
about the normal physiological role of PTP1B in the mammary gland before this 
study. PTP1B was suggested to play a role in normal mammary gland development by 
regulating the prolactin-mediated activation of STAT5, a key regulator of mammary 
gland development and differentiation. While informative, these findings were based 
on knockdown experiments in breast cancer cell lines, which may not accurately 
reflect the in vivo situation. Therefore, in this study we took advantage of a PTP1B 
knockout mouse model to gain a deeper knowledge on the role of this phosphatase 
plays in mammary cell fate and mammary gland development. 
We found that loss of PTP1B increases the number of mammary alveolar progenitors, 
enhancing the pool of cells able to generate alveolar structures during pregnancy. 
Consistently, we observed an increase in alveolar density in glands from PTP1B
-/- 
mice.
 
We also found that deletion of PTP1B increased expression of milk proteins 
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during late pregnancy. We showed that these phenotypes are mediated by precocious 
phosphorylation and activation of the transcription factor STAT5 and/or by increased 
expression of the progesterone receptor, two key regulators of mammary gland 
development and differentiation. These observations provide new insight into the 
signaling cascades that regulate mammary stem/progenitor cells differentiation and 
lineage commitment during mammary gland development. 
In summary, we identified new functions for PTP1B in mammary gland 
alveologenesis and lactogenesis. The absence of PTP1B protects from, or delays 
HER2/Neu evoked mammary tumors in mice. Our studies raise the possibility that the 
change in mammary cell fate seen in glands lacking PTP1B may contribute to the 
observed cancer protective effect, a question that warrant further investigation. 
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3.  INTRODUCTION 
 
3.1 Mammary gland development and breast cancer 
 
The mammary gland consists of a tree-like structure composed of hollow ducts and 
alveoli. It is composed of several cell types organized in two main compartments: the 
epithelium composed of luminal epithelial and myoepithelial cells forming the 
bilayered ductal lobular network; and the stroma, consisting mainly of adipocytes and 
fibroblasts. The mammary gland is the only organ that undergoes most of its 
development after birth and goes through repeated cycles of proliferation, 
differentiation and apoptosis during each round of pregnancy. These characteristics 
make the mouse mammary gland a suitable organ for biological research on 
developmental processes. Epidemiological studies have shown that early menarche, 
late menopause and late age of first pregnancy are all risk factors for developing 
sporadic breast cancer (Kampert, Whittemore et al. 1988). Clearly the hormonal 
milieu and breast development cycles, probably through changes in the differentiation 
state of breast stem/progenitor cells, affect the susceptibility of the breast to 
oncogenic transformation. Therefore, understanding the mechanisms regulating 
normal mammary gland development is of major importance for understanding breast 
tumorigenesis. 
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3.2 Mammary gland development  
 
The human and rodent mammary gland essentially develops during three stages, in 
which different signaling networks are activated: embryonic, pubertal and adult (Fig 
1). (Richert, Schwertfeger et al. 2000; Hennighausen and Robinson 2005; Brisken and 
O'Malley 2010) 
 
Figure 1. Stages of mouse mammary gland development. Schematic presentation of the different stages of 
mammary gland development and differentiation. 
 
 
3.2.1 Embryonic and pubertal stages of mammary gland development 
 
During embryogenesis a small, rudimentary ductal system arises as an appendix of the 
ventral skin, which grows after birth isometrically to the rest of the body until 
puberty. Several studies observed that the embryonic stage is independent of 
circulating hormones, but is regulated by a sequential and reciprocal cross-talk 
between the epithelium and the surrounding mesenchyme (Robinson 2007; Watson 
and Khaled 2008). During puberty the increased level of ovarian steroid hormones 
induces the formation of terminal end buds (TEBs) at the tips of the ducts. These are 
club-shaped structures with highly proliferative and migratory properties. The TEBs 
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consist of an outer single layer of cap cells and an inner core formed by multiple 
layers of body cells. Under hormonal stimulation, the body cells proliferate inducing 
the elongation of the ducts in the surrounding stroma (also called fat pad) (Howlin, 
McBryan et al. 2006). Bifurcation of TEBs induces the formation of new primary 
ducts and together with lateral sprouting of secondary side-branches they fill the 
entire fat pad with a tree-like ductal network (Sternlicht 2006). This process is 
controlled by a number of paracrine, juxtacrine and autocrine factors; including 
hormones, growth factors, extracellular matrix molecules, matrix metalloproteases 
and morphogens (Sternlicht, Kouros-Mehr et al. 2006). A central role is played by the 
ovarian steroid hormone estrogen. Of the two estrogen receptor (ER) isoforms, ER 
and ER, epithelial ER is essential for ductal outgrowth, whereas ER and stromal 
ER are dispensable for mammary gland development (Krege, Hodgin et al. 1998; 
Mallepell, Krust et al. 2006). ER-/- mice display an underdeveloped epithelial duct, 
but maintain the capacity for alveolar expansion during pregnancy (Bocchinfuso, 
Lindzey et al. 2000). ER stimulates proliferation and morphogenesis in a paracrine 
fashion by inducing the expression of amphiregulin (AREG). AREG is a member of 
the epidermal growth factor receptor (EGFR) family of ligands that binds EGFR on 
neighboring cells stimulating their proliferation. Analysis of AREG-null mammary 
glands shows that AREG is essential for ductal elongation as well as estrogen-induced 
proliferation and terminal end bud formation (Ciarloni, Mallepell et al. 2007). 
The adult mature virgin gland is essentially quiescent with the exception of the 
limited ductal side-branching and alveolar bud formation that occur as a result of the 
cyclic increase of ovarian hormones during the estrous cycle.  
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3.2.2 Pregnancy stages of mammary gland development 
 
With the onset of pregnancy, extensive epithelial proliferation and tertiary side- 
branching occur with the formation and differentiation of a lobular alveolar system 
able to express and secrete milk during late pregnancy. 
The complex and coordinated mechanisms governing the extensive 
morphological and cellular changes underlining mammary gland differentiation are 
mainly regulated by the steroid hormone progesterone, and the pituitary polypeptide 
hormone, prolactin. 
Several studies demonstrated that progesterone induces extensive side-branching and 
formation of alveolar structures (process known as alveologenesis) during the early 
stages of pregnancy (Conneely, Mulac-Jericevic et al. 2007). Progesterone actions are 
mediated by the progesterone receptor (PR). In the absence of PR, the mammary 
gland displayed normal growth but failed to side branch and to form alveolar 
structures when exposed to hormonal stimuli (Lydon, DeMayo et al. 1995). PR occurs 
in two isoforms, PRA and PRB, which display differential transcription activities. 
Gene targeting experiments revealed that deletion of PRB displayed a phenotype 
similar to the complete PR mutant mammary gland, whereas absence of PRA did not 
impair mammary gland development. These results indicate PRB as the predominant 
mediator of progesterone action in mammary gland morphogenesis. The adult 
mammary gland displayed a nonuniform expression pattern of PR. It localizes in a 
scattered subset of epithelial cells along the ductal epithelium (Silberstein, Van Horn 
et al. 1996), indicating that not all epithelial cells are able to respond directly to 
progesterone. Analysis of cellular proliferation of the mammary gland in early   
pregnancy revealed that PR-positive cells located closely to proliferating epithelial 
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cells (Russo, Ao et al. 1999), suggesting that progesterone-induced proliferation is 
mediated through paracrine activities. This observation was further confirmed by the 
elegant experiment in which a mixture of PR
-/-
 and PR
+/+
 cells was used to 
reconstitute wild type cleared fat pads. PR
-/- 
cells, which by themselves cannot form 
side-branches and alveoli, can participate in the development of side-branches and 
alveoli when they are in close proximity to wild type cells (Brisken, Park et al. 1998). 
Therefore, PR seems to induce the expression of secreted factors, which induce the 
proliferation of neighboring cells. One candidate mediator of the progesterone 
response is WNT4, a secreted glycoprotein essential for regulating ductal branching 
(Brisken, Heineman et al. 2000). However, unlike PR-null mice, the morphogenic 
defects in WnNT4 knockout mice are overcome in late pregnancy, suggesting that 
additional progesterone downstream targets exist to mediate progesterone-response in 
the mammary gland. A further candidate is the receptor activator of nuclear factor kB 
(NF-kB) ligand (RANK-L, also known as OPGL), a member of the tumor necrosis 
factor (TNF) superfamily, which plays an important role in osteoclast development 
(Kong, Yoshida et al. 1999). Deletion of RANK-L or its receptor Rank from the 
mammary gland attenuated alveologenesis resulting in a lactational defect (Fata, 
Kong et al. 2000), a phenotype similar to PR knockout mice. RANK-L was proposed 
to mediate the parity-induced morphological changes by inducing activation of NF-kB 
and expression of cyclin D1 (Cao, Bonizzi et al. 2001; Fernandez-Valdivia, 
Mukherjee et al. 2009; Beleut, Rajaram et al. 2010).  RANK-L expression was also 
shown to be regulated by the second key player of mammary gland differentiation: 
prolactin (PRL) (Ormandy, Naylor et al. 2003), revealing the existence of a complex 
interaction between different signaling pathways in the regulation of the extensive 
morphological changes underlining mammary gland differentiation.  PRL is a peptide 
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hormone expressed mainly by the pituitary gland (Freeman, Kanyicska et al. 2000), 
but also by several extrapituitary sites such as mammary gland, placenta and uterus 
(Ben-Jonathan, Mershon et al. 1996). Prolactin signaling is mainly mediated via the 
PrlR-JAK2-STAT5 pathway (Gouilleux, Wakao et al. 1994; Liu, Robinson et al. 
1995). PRL binds and activates the prolactin receptor (PrlR), a class I cytokine 
receptor superfamily member (Boutin, Jolicoeur et al. 1988), which will then dimerize 
and lead to the activation of the associated kinase JAK2. JAK2 in turn phosphorylates 
the signal transducers and activators of transcription 5 (STAT5), which will dimerize 
and translocate to the nucleus where it can induce the transcription of genes involved 
in alveolar morphogenesis or lactation like the milk protein -casein (Wartmann, 
Cella et al. 1996). 
The role of PRL during mammary gland development and differentiation has 
been explored using PRL and PrlR knockout mouse models. The development of the 
mammary glands in these models exhibits normal proliferation, ductal elongation and 
bifurcation during puberty, suggesting that PRL and PrlR are not required for these 
morphological changes. However, ductal side branching, alveologenesis and 
lactogenesis are severely disrupted in both PRL
-/-
 and PrlR
-/- 
mammary glands 
(Horseman, Zhao et al. 1997; Ormandy, Camus et al. 1997; Brisken, Kaur et al. 1999; 
Vomachka, Pratt et al. 2000). Furthermore, JAK2 and STAT5 knockout mice 
phenocopied the failed lobuloalveolar development observed in PRL
-/-
 and PrlR
-/- 
(Liu, Robinson et al. 1997; Wagner, Krempler et al. 2004), indicating an essential role 
for the PRL-JAK2-STAT5 pathway in alveolar morphogenesis and milk secretion in 
the mammary gland. 
The use of microarray technology allowed the identification of several PRL 
transcription targets shedding light on the complex regulatory network induced by 
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PRL signaling pathway (Ormandy, Naylor et al. 2003; Harris, Stanford et al. 2006). 
Among the different targets found to be regulated by the PRL pathway are the well 
known RANK-L and amphiregulin, the transcription factors GATA3 and ELF5 
shown to regulate luminal cell differentiation (topic developed in the next session) 
and connexin 26, component of the gap junction complex shown to be necessary to 
the integrity of the forming alveoli. Signaling via the PRL-JAK2-STAT5 pathway 
culminates with the expression and secretion of milk proteins. Signaling via this 
pathway is, therefore, highly regulated by different enhancers and inhibitors acting to 
modulate PRL signaling. ERBB4 and 1-integrin have been shown to act as enhancer 
by regulating STAT5 phosphorylation (Long, Wagner et al. 2003; Naylor, Li et al. 
2005). Negative feedback regulation is provided by members of the suppressors of 
cytokine signaling (SOCS) family of proteins, the expression of which is induced by 
PRL and acts by inhibiting the PRL signaling pathway via different mechanisms 
(Oakes, Rogers et al. 2008). Finally, Caveolin 1 was discovered to abrogate PRL 
signaling pathway by sequestering JAK2, such that it can no longer activate STAT5 
(Park, Lee et al. 2002). Although different studies enabled the elucidation of several 
parts of the complex signaling network coordinating mammary gland differentiation, 
the complete picture underlying the molecular and cellular events is not completely 
understood. 
 
3.2.3 Lactation and involution of the mammary gland 
 
During lactation the expressed milk is secreted in the lumen of the alveoli allowing 
the feeding of the young (Neville, McFadden et al. 2002; Rudolph, McManaman et al. 
2007). When the pups are weaned, the loss of suckling stimuli and milk stasis induce 
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a complex remodeling program called involution (Green and Streuli 2004; Watson 
2006).  The initial phase of involution is characterized by a reversible induction of 
apoptosis of differentiated epithelial cells. After a prolonged absence of suckling, 
apoptosis is accompanied by the collapse of the alveolar structures, and an irreversible 
remodeling of the mammary gland into a virgin-like ductal structure (Lund, Romer et 
al. 1996). The involuted gland is now ready for a next round of pregnancy. 
 
3.3 The mammary gland cellular hierarchy 
 
The extensive regeneration potential of the mammary gland with each round of 
pregnancy suggested the presence of stem cell activity within this organ. Adult stem 
cells are long-lived, quiescent cells that are able to self-renew, maintaining the stem 
cell pool, and to give rise to a variety of differentiated cells (Reya, Morrison et al. 
2001; Molofsky, Pardal et al. 2004). The first hints of the existence of a mammary 
stem cell (MaSC) were discovered around 50 years ago by DeOme and colleagues 
(Deome, Faulkin et al. 1959) with the observation that transplantation of tissue 
fragments of epithelium isolated from different regions of the mammary gland were 
able to reconstitute a complete, functional mammary ductal tree containing both 
epithelial and myoepithelial cells. Further studies demonstrated that MaSCs were 
present in all portions of the ductal network, independently of the developmental 
stage of the mammary gland (Smith and Medina 1988). Limiting dilution experiments 
and retroviral marking of mammary epithelial cells (Smith 1996; Kordon and Smith 
1998) suggested the existence, besides of multipotent stem cells, of two further 
distinct progenitor cells with limited potential: the alveolar progenitors that give rise 
to the secretory lobules, and the ductal progenitors giving rise to the ductal network of 
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the mammary gland. These results suggest the existence of a stem cell hierarchy in the 
mammary gland, which starts from stem cells with high proliferation, differentiation 
and self-renewal capacities, progressing via intermediate progenitor cells and ending 
in the differentiated epithelial cells, with limited self-renewal potential. Considerable 
progresses have recently been made in the isolation and characterization of functional 
MaSCs. Three complementary studies identified surface markers: CD24 (heat stable 
antigen), CD29 (-integrin) and CD49f (6-integrin), that are able to phenotype and 
functionally isolate single cells competent to reconstitute a complete, functional 
mammary gland when transplanted into cleared fat pad of recipient mice (Shackleton, 
Vaillant et al. 2006; Sleeman, Kendrick et al. 2006; Stingl, Eirew et al. 2006). Further 
characterization of these cells revealed that MaSCs belong to the basal compartment 
of the epithelium (showing low expression of CD24 like the basal myoepithelial cells) 
and that they were negative for the expression of ER (Sleeman, Kendrick et al. 
2007). These studies demonstrated that a population enriched for MaSCs is present in 
the mammary gland and is characterized by low expression of CD24 and high 
expression of CD29 and/or CD49f (CD24
+
CD29
hi
 or CD24
+
CD49f
hi
 cells). These and 
other studies provided evidence for a hierarchical model of epithelial cells in which 
MaSCs give rise to progressively restricted progenitors that culminate in the two 
differentiated epithelial and myoepithelial cells. Recent studies enabled the isolation 
and characterization of distinct progenitor cells by means of different surface markers. 
CD61 (3-integrin) was shown to be a luminal epithelial progenitor marker (Asselin-
Labat, Sutherland et al. 2007), c-Kit (CD117) marks early stage progenitor cells in the 
basal compartment and highly proliferative progenitor cells in the luminal 
compartment (Regan, Kendrick et al. 2011), and ALDH was shown to stain 
stem/progenitor cells (Ginestier, Hur et al. 2007). 
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Various models exist in the field for the mammary stem cell hierarchy. A 
possible model suggested by Visvader et al. proposed the existence of myoepithelial 
progenitors that give rise to myoepithelial cells, and a common luminal progenitor 
population that give rise to ductal luminal and alveolar luminal epithelial cells (Fig 2) 
(Visvader and Lindeman 2006; Asselin-Labat, Sutherland et al. 2007). Smith and 
coworkers suggested the existence of alveolar progenitors and ductal progenitors that 
give rise to both epithelial and myoepithelial cells in the two different structures of the 
mammary gland (Smith 1996). These models are not mutually exclusive; however, 
further studies are needed to understand how these findings can be combined in a 
common mammary stem cell hierarchy. 
 
 
Figure 2. Mammary stem cell hierarchy. Regulation of mammary stem cells by hormones, growth factors, and 
transcription factors during lineage commitment. (adapted from LaMarca and Rosen 2008). 
 
Several studies revealed that lineage commitment within the mammary stem 
cell hierarchy seems to be regulated by the action of different transcription factors. 
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GATA3 and ELF5 were shown to regulate luminal cell differentiation in the 
mammary gland (Asselin-Labat, Sutherland et al. 2007; Oakes, Naylor et al. 2008). 
Furthermore recent studies have shown that STAT5, besides its well known role in 
secretory differentiation and milk expression, also plays a crucial role in the 
establishment of luminal alveolar progenitor cells (Yamaji, Na et al. 2009). Loss of 
STAT5 resulted in a failure of the primitive SC/progenitor cells to generate alveolar 
luminal progenitor cells visible by a reduction in the proportion of luminal progenitor 
cells (CD61
+
 cells) at the virgin stage. Although progress has been made in the 
elucidation of the MaSC hierarchy, the precise mechanisms that regulate 
stem/progenitor differentiation and lineage commitment during mammary gland 
development remain elusive. It is important to deeper understand the signaling 
mechanisms involved in cell fate commitment in order to determine how these signals 
are altered in mammary gland tumorigenesis. 
. 
3.4 Breast cancer  
 
Breast cancer is the most frequently diagnosed cancer in women (Ferlay, Autier et al. 
2007; Jemal, Bray et al. 2011) with an estimated 1.4 million new cancer cases 
diagnosed per year worldwide (23% of all cancers) (Jemal, Bray et al. 2011). Breast 
cancer arises from the epithelial compartment of the mammary gland and progresses 
into hyperplasia, atypical hyperplasia, ductal carcinoma in situ (DCIS) and invasive 
carcinoma (IDC) (Bombonati and Sgroi 2011). With each step the tumor becomes 
progressively aggressive and culminates in the often fatal invasive carcinoma were 
the epithelial cells invade the surrounding breast and metastasize to distant organs 
such as lung, bone, liver and brain (Nguyen, Bos et al. 2009). 
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Currently the different types of breast cancers are clinically characterized by the 
histological grade of the tumor (differentiation status), lymph node status and the 
expression of the hormone receptors ER, PR, and the tyrosine kinase receptor HER2 
(ERBB2). However, due to the heterogeneity of breast cancers exhibiting different 
molecular alterations that drive their growth, survival and metastatic properties, the 
markers used are not exhaustive enough. Recently, genome-wide gene-expression 
profiles enabled the classification of breast cancer into 6 subgroups with different 
prognosis (Perou, Sorlie et al. 2000; Sorlie, Perou et al. 2001; Prat, Parker et al. 2010). 
The luminal A and luminal B subgroups account for 60% of breast cancers and are 
characterized by the expression of luminal markers like cytokeratin 8/18 and ER 
with or without the coexpression of PR (Sims, Howell et al. 2007). A second subtype 
is the HER2-enriched breast cancer, characterized by the overexpression of HER2. It 
accounts for 20% of breast cancers and is associated with an aggressive disease and 
decreased survival (Slamon, Clark et al. 1987). The normal-like type of breast cancer 
shows an expression profile similar to normal breast samples. Finally the basal-like 
and claudin-low tumors, also known as triple-negative breast cancers (TNBC) due to 
the lack of expression of ER, PR and of amplification of HER2, account for 20% of 
the patients and correlate with the worst prognosis due also to the lack of effective 
therapy (Sims, Howell et al. 2007). This new classification of breast cancers enables a 
better prediction of tumor response to chemotherapy and opens the possibility to 
develop novel targeted therapies against specific subtypes of breast cancer. 
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3.5 How does mammary gland development and differentiation relate to human 
breast cancer? 
 
Epidemiologic studies revealed that susceptibility of breast epithelium to develop a 
tumor is influenced by hormonal changes that affect normal mammary gland 
development (e.g. age of menarche, age of first pregnancy and age of menopause) 
(MacMahon, Cole et al. 1970; Brinton, Schairer et al. 1988; Kampert, Whittemore et 
al. 1988). These studies demonstrated that parous females have up to 50% reduction 
in lifespan breast cancer risk compared with nulliparous females, and that the timing 
of the first pregnancy plays a significant role in parity-induced protection. Several 
possible mechanisms mediating this protection have been suggested, including 
changes in the hormonal profile of parous women, or a more differentiated, and hence 
less susceptible mammary gland (Thordarson, Jin et al. 1995; D'Cruz, Moody et al. 
2002; Sivaraman and Medina 2002; Russo, Moral et al. 2005). However, the 
molecular mechanisms underlying parity-induced protection remain elusive. 
Therefore, a deeper understanding of mammary gland differentiation is important to 
elucidate this effect. 
In addition, the demonstration of the presence of a stem cell hierarchy in the 
mammary gland and human breast raised the hypothesis that the heterogeneity of 
breast cancers could be due to oncogenic transformation of cells with distinct 
differentiation states (Melchor and Benitez 2008). Therefore, investigation of the 
mechanisms regulating stem/progenitor cell renewal and commitment in normal 
mammary gland may provide new insights in breast cancer development. 
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 Therefore, it is important to better understand the pathways regulating 
mammary gland development and cell fate commitment in normal tissue in order to 
shed light into tumorigenesis and breast cancer heterogeneity. 
 
3.6 Protein-tyrosine phosphatases 
 
Protein-tyrosine phosphorylation plays an important regulatory role in different 
biological processes including proliferation, differentiation, apoptosis and migration. 
Tyrosyl-phosphorylation is tightly regulated by the combined action of protein-
tyrosine kinases (PTKs) and protein tyrosine-phosphatases (PTPs) (Fig 3). Not 
surprisingly, deregulated tyrosyl-phosphorylation underlies various diseases of 
deregulated growth and differentiation, including cancer. 
Initially PTPs were thought to play simply a counteracting role to PTKs. 
However, it is now clear that they also play an active role in the regulation of many 
physiological processes. PTKs and PTPs act in a coordinated way in which PTKs 
regulate the amplitude of a signaling response, whereas PTPs are thought to play a 
role in controlling the rate and duration of a response (Heinrich, Neel et al. 2002; 
Hornberg, Bruggeman et al. 2005). 
 
Figure 3. The coordinated action of PTKs and PTPs regulates tyrosine phosphorylation. Tyrosine 
phosphorylation is a key mechanism for signal transduction and for the regulation of many physiological 
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processes. Proteins are phosphorylated on tyrosine residues by PTKs and dephosphorylated by PTPs (Mustelin, 
Vang et al. 2005). 
 
 
The human genome encodes ~107 PTPs that equal the diversity and 
complexity of PTKs (Alonso, Sasin et al. 2004). All members of the PTP family are 
characterized by the catalytic-site motif HCXXGXXR, which contains a conserved 
cysteine residue essential for catalysis (Andersen, Mortensen et al. 2001). Tyrosyl-
phosphorylation occurs in a two-step mechanism. First the sulfur atom of the thiolate 
side chain of the cysteine nucleophilically attacks the phosphate while the conserved 
aspartic acid residue protonates the tyrosyl-leaving group of the substrate. This leads 
to the formation of a cystenil-phosphate catalytic intermediate, which will then be 
hydrolyzed by a glutamine and an aspartic residue, in the second step, causing the 
release of the phosphate group (Tonks 2003). 
The PTP superfamily is divided into two categories: the classical 
phosphotyrosine-specific phosphatases, characterized by their specificity for 
phosphotyrosine residues; and the dual specificity phosphatases that can 
dephosphorylate phosphoserine/phosphothreonine residues as well as phosphotyrosine 
residues (Alonso, Sasin et al. 2004; Andersen, Jansen et al. 2004). The classical PTPs 
comprise 38 PTP members in rat and mouse, and 37 members in the human genome 
(OST-PTP is thought to be a pseudogene in human). This group can be further 
subdivided into two subgroups, the transmembrane receptor like proteins (RPTP) and 
the non-transmembrane, cytoplasmatic PTPs (Fig 4) (Andersen, Mortensen et al. 
2001).  
The transmembrane PTPs contain a variable extracellular domain responsible 
for cell-cell, cell-matrix and cell-ligand interaction, a single-pass transmembrane 
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domain and an intracellular domain containing one or tandem PTP domains (with the 
major catalytic activity in the membrane-proximal domain) (Streuli, Krueger et al. 
1990; Felberg and Johnson 1998). The cytoplasmatic PTPs are characterized by 
different non-catalytic, regulatory sequences important for the activity of the 
phosphatase; regulation mediated by direct interaction with the active site, by 
controlling substrate specificity or by controlling the subcellular localization of the 
phosphatase (Garton, Burnham et al. 1997; Pulido, Zuniga et al. 1998). 
 
 
Figure 4. The family of classical PTPs. Classical PTPs can be categorized as transmembrane or non-
transmembrane proteins (Soulsby and Bennett 2009). 
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3.7 Regulation of classical PTPs 
 
Because the appropriate control of protein-tyrosine phosphorylation is essential for 
cellular homeostasis, PTPs are tightly regulated by a variety of mechanisms including 
gene expression, protein localization and post-translational modifications. With the 
last being a fast and often reversible mechanism to fine-tune tyrosine 
phosphorylation-dependent signaling pathways. 
An important post-translational modification is reversible oxidation of PTPs 
(Meng, Fukada et al. 2002). The essential cysteine residue of the PTP catalytic motif 
is characterized by unusual low pK (Groen, Lemeer et al. 2005; Salmeen and 
Barford 2005). Therefore, at neutral pH the cysteine is present predominantly as 
thiolate anion. This enhances the neutrophilic property of the cysteine and at the same 
time renders the PTP more susceptible to oxidation and thus to its inhibition. Reactive 
oxygen species (ROS), produced in a variety of physiological stimuli such as growth 
factors or antigen receptors, oxidize the thiolate anion of the essential cysteine into 
sulfenic acid (-SOH). In this form, the cysteine residue can no longer function as a 
nucleophile and therefore inhibits PTPs activity. Importantly, this oxidation and the 
concomitant inhibition of PTPs are reversible allowing a rapid and dynamic 
regulation of PTPs (Denu and Tanner 1998). 
PTPs can be further regulated through phosphorylation, nitrosilation and/or 
sumoylation. Phosphorylation of tyrosine residues (e.g., in PTP1B, SHP1, SHP2 and 
PTP) or serine residues (e.g., in PTPN12) affects their phosphatase activity and their 
affinity to substrates or interacting partners (Bennett, Tang et al. 1994; den Hertog, 
Tracy et al. 1994; Dadke, Kusari et al. 2001). In addition PTP1B can also be modified 
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by the small ubiquitin-like modifier (SUMO), which was shown to decrease its 
activity (Dadke, Cotteret et al. 2007). 
Proteolytic cleavage of regulatory domains of the PTPs is another post-
translational mechanism suggested to regulate their activity. Upon calpain-mediated 
cleavage the catalytic activity of PTP1B, PTP-MEG1 and SHP1 were shown to be 
increased (Frangioni, Oda et al. 1993; Gu, Meng et al. 1996; Falet, Pain et al. 1998). 
In addition, the cleavage of the extracellular domain of the transmembrane PTPs like 
LAR, PTP and PTP was also shown to be important for regulating their 
phosphatase function (Streuli, Krueger et al. 1992; Anders, Mertins et al. 2006; Ruhe, 
Streit et al. 2006) 
Transmembrane PTPs can be additionally regulated by binding to their ligands and/or 
by their dimerization. Ligand binding can have opposing effects on the phosphatase 
activity. For example the phosphatase function of LAR can be activated by binding to 
the transmembrane protein syndecan (Sdc) or inhibited by binding to the 
glycosylphosphatidylinositol-anchored protein dallylike (Dlp) (Fox and Zinn 2005; 
Johnson, Tenney et al. 2006). 
 
3.8 PTPs and human disease 
 
Several evidences have shown that members of the PTP superfamily are key 
components of tumorigenesis in various human cancers. PTPs were initially thought 
to act exclusively as tumor suppressors because of their counteracting role to PTKs, 
known to have relevant functions in cancer development. However, it is now clear 
that individual PTPs play also an active role in the regulation of many physiological 
processes; as such these PTPs may exert oncogenic functions. A well-known tumor 
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suppressor among the 107 members of the PTP superfamily is the lipid phosphatase 
PTEN. PTEN was shown to dephosphorylate phosphatidylinositol(3,4,5)-
trisphosphate (PIP3) and thereby it opposes the activity of the oncogene PI3K. 
Somatic mutation analysis of human cancers showed a high frequency of mutations 
specifically for the PTEN gene resulting in an increased activity of the PI3K pathways 
associated with cell survival (Li, Yen et al. 1997; Myers, Pass et al. 1998; Wu, 
Senechal et al. 1998). Other PTPs have been suggested as tumor suppressors in breast 
cancer like PTPN12 (Sun, Aceto et al. 2011) PTP (Panagopoulos, Pandis et al. 1996; 
Zheng, Kulp et al. 2000) PTP-BAS (Bompard, Puech et al. 2002; Freiss, Bompard et 
al. 2004) MEG2 (Yuan, Wang et al.), GLEPP1 (Ramaswamy, Majumder et al. 2009) 
and PTP (Perez-Pinera, Garcia-Suarez et al. 2007) (for a detailed review (Ostman, 
Hellberg et al. 2006)). 
By contrast, SHP2 (Chan, Kalaitzidis et al. 2008), PTP(Ardini, Agresti et al. 
2000; Zheng, Resnick et al. 2008), LAR (Yang, Zhang et al. 1999; Levea, McGary et 
al. 2000), PTPH1 (Zhi, Hou et al.) and PTP1B (discussed in section 3.11) were shown 
to have oncogenic role in breast cancers. SHP2 (PTPN11), for example, transduces 
mitogenic and pro-migratory signals from various types of receptors. SHP2 was 
shown to be hyperactivated either by mutations or downstream of oncoproteins in 
several types of tumors, like juvenile myelomonocytic leukemias, gastric carcinoma, 
anaplastic large cell lymphoma and glioblastoma (Tartaglia, Niemeyer et al. 2003; 
Chan, Kalaitzidis et al. 2008; Zhan, Counelis et al. 2009). 
It is important to note that aberrant regulation of PTP-superfamily members is 
also associated with diseases other than cancer. Mutation of PTP Lyp (PTPN22) was 
shown to be a common risk factor for autoimmune diseases, including type I diabetes 
(Bottini, Musumeci et al. 2004). Early characterization of PTP1B illustrated its ability 
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to antagonize insulin and leptin signaling pathways. Alteration in the level of 
expression or activity of PTP1B was shown to play a role in obesity and diabetes, 
waking up a great interest in the development of novel therapies against PTP1B to 
cure obesity and diabetes mellitus II. 
In light of the implications of PTPs in several diseases it is of high importance 
to physiologically and functionally characterize the PTP superfamily in order to 
implement the development of PTP-based therapeutics. 
 
3.9 Protein tyrosine phosphatase 1B 
 
Protein tyrosine phosphatase 1B (PTP1B) was the first PTP to be purified (Tonks, 
Diltz et al. 1988) and the first, with its close homolog TC-PTP, to be cloned (Cool, 
Tonks et al. 1989; Chernoff, Schievella et al. 1990). PTP1B is the founding and 
prototype enzyme of the PTP superfamily; some futures of this family like structure, 
function and regulation were first discovered in the context of PTP1B and than proven 
for other members of this family. 
PTP1B is a non-transmembrane, cytoplasmatic PTP encoded by the gene 
PTPN1 located on chromosome 20 (region q13.1-q13.2) in human and on 
chromosome 2 (region H2-H3) in mouse (Brown-Shimer, Johnson et al. 1990; Forsell, 
Boie et al. 2000). PTP1B is a ubiquitously expressed 435-amino acid 50 kDa protein, 
composed by an N-terminal catalytic domain, two proline-rich motifs and a C-
terminal hydrophobic region (Fig 5) (Stuible, Doody et al. 2008; Lessard, Stuible et 
al. 2010). The C-terminal hydrophobic domain anchors the protein to the cytoplasmic 
face of the endoplasmatic reticulum. The proline-rich motifs are binding sites for 
SH3-domain containing proteins such as p130CAS, GRB2 and many more. The N-
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terminal catalytic domain contains the active site with the essential cysteine amino 
acid involved in the dephosphorylation of PTP1B substrates. The crystal structure of 
this domain, the first to be solved for a member of the PTP superfamily (Barford, 
Flint et al. 1994), revealed a domain organization into eight -helices and 12 -
strands with a 10-stranded mixed -sheet. The signature motif, which forms the 
phosphate recognition site, is located at the base of a cleft, with the invariant aspartic 
acid and glutamine residues located on the side of the cleft. The depth of the cleft 
contributes to the specificity of PTP1B for phosphotyrosine substrates because the 
small phosphoserine and phosphothreonine residues are not able to reach the 
phosphate-binding site at the base of the cleft. 
 
 
 
Figure 5. Structural domains and regulation of PTP1B. Schematic representation of the domain structure of 
PTP1B. Full-length human PTP1B is composed of an N-terminal catalytic domain (green) and C-terminal ER 
targeting domain (orange), flanking two proline-rich domains (purple), at least one of which is critical for protein–
protein interactions. PTP1B is regulated by tyrosine phosphorylation, and serine phosphorylation at the indicated 
sites, oxidation of Cys215 at its active site, sumoylation at its PRD, and proteolysis by calpain (Yip, Saha et al. 
2010). 
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The catalytic activity of PTP1B is tightly controlled. First, its localization to the ER 
may restrict its access to substrates often localized at the plasma membrane. Several 
studies suggested that PTP1B dephosphorylates ligand-activated receptor PTKs after 
their internalization (Haj, Verveer et al. 2002). Furthermore, PTP1B could directly 
dephosphorylate receptor PTKs at the plasma membrane due to the flexible nature of 
the endoplasmatic reticulum, which seems to extend under certain circumstance until 
the plasma membrane (Hernandez, Sala et al. 2006). PTP1B can be released from its 
location by calpain-mediated proteolytic cleavage. Depending on the context, PTP1B 
release allows it to access a larger set of substrates or to be targeted for degradation. 
PTP1B, like other PTPs, can be regulated by oxidation of the catalytic cysteine. 
Several external stimuli, including EGF, insulin and other growth factors, generate 
reactive oxygen species upon stimulation, which will lead to the oxidation and 
inactivation of PTP1B, thereby enhancing phosphotyrosine-mediated signaling 
(Meng, Buckley et al. 2004). PTP1B is further regulated by phosphorylation at 
multiple serine and tyrosine sites (Brautigan and Pinault 1993; Ravichandran, Chen et 
al. 2001; Tao, Malbon et al. 2001). However, the effects of phosphorylation on 
PTP1B activity are controversial. PTP1B can also be regulated by SUMO 
conjugation. Studies have shown that insulin transiently stimulates PTP1B 
sumoylation decreasing its dephosphorylation function (Dadke, Cotteret et al. 2007). 
Besides post-translational modification PTP1B can be regulated at the 
transcriptional level. Several reports suggest that PTP1B levels are modulated by 
BCR-ABL, the tyrosine kinase responsible for chronic myelogenous leukemia 
(CML). BCR-ABL enhances PTP1B expression by binding to the p210 BCR-ABL 
responsive sequence (PRS) present in its promoter, in response to PTK stimulation 
(Fukada and Tonks 2001). A further candidate for the regulation of PTP1B expression 
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is the transcription factor Y-box-binding protein 1 (YB-1), since analysis of PTP1B 
promoter characterized an enhancer sequence that serves as binding sites for YB-1 
(Fukada and Tonks 2003). PTP1B mRNA levels are modulated in various types of 
cancer, for example it is downregulated in oesophageal cancer lesions and 
overexpressed in epithelial carcinomas, ovarian carcinomas and human breast 
carcinoma cells (reviewed in Dube and Tremblay 2004). 
 
3.10 Substrates of PTP1B 
 
Numerous substrates have been identified for PTP1B, involved in multiple cell 
processes such as glucose uptake, proliferation, differentiation, apoptosis, cell-cell 
adhesion, extracellular matrix attachment, motility and invasion (reviewed by 
(Stuible, Doody et al. 2008). They include receptor PTKs like EGFR (Flint, Tiganis et 
al. 1997; Haj, Markova et al. 2003), PDGFR (Haj, Markova et al. 2003; Dube, Cheng 
et al. 2004), IR and IGF-1R (Buckley, Cheng et al. 2002). Intracellular PTKs such as 
SRC (Bjorge, Pang et al. 2000), BCR-ABL (LaMontagne, Hannon et al. 1998), JAK2 
and TYK2 (Myers, Andersen et al. 2001) are also substrate of PTP1B. In addition, 
adapter proteins for example p130CAS, cytoskeletal proteins like -catenin (Balsamo, 
Leung et al. 1996) and transcription factors like STAT5 (Johnson, Peck et al. 2010) 
have also been shown to be targets of PTP1B. The identification of PTP1B substrates 
was achieved by the use of substrate trapping mutant, in which substitution of a 
cysteine in the catalytic center (Cys 215 for PTP1B) or the invariant asparagine (Asp 
181 in PTP1B) generates a form of PTP1B that maintains a high affinity for substrates 
but doesn’t have catalytic activity (Flint, Tiganis et al. 1997). This mutant can form 
stable enzyme-substrate complexes, which allow the identification of substrates by 
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immunoprecipitation. Single substrates were further validated by gene-targeting 
techniques in vitro and/or in vivo. One of the best understood PTP1B substrates are 
the insulin receptor (IR) and JAK2 proteins (Fig 6). Several in vitro and in vivo 
studies demonstrated that PTP1B regulates metabolic processes maintaining glucose 
homeostasis and body mass by dephosphorylating and inhibiting IR and JAK2 
(Elchebly, Payette et al. 1999; Klaman, Boss et al. 2000). PTP1B knockout mice are 
healthy and exhibit insulin sensitivity, correlating with a decreased level of circulating 
insulin and an increased IR phosphorylation. They are lean and resistant to high fat 
diet-induced obesity, suggesting the involvement of PTP1B in the regulation of the 
leptin signaling. Furthermore, they are hypersensitive to leptin treatment, an effect 
associated with elevated phosphorylation and activation of JAK2 and its target 
STAT3 (Cheng, Uetani et al. 2002; Zabolotny, Bence-Hanulec et al. 2002). 
 
Fig 6. Metabolic signaling of PTP1B. PTP1B attenuates insulin signaling by dephosphorylating IR and IRS-1 and 
the leptin pathway by dephosphorylating JAK2. 
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In addition to its negative role on the IR, PTP1B can also dephosphorylate other 
receptor PTKs, including the EGF and platelet-derived growth factor (PDGF) 
receptors. Studies using fluorescence resonance energy transfer demonstrated that 
PTP1B dephosphorylated EGF and PDGF receptors after their internalization by 
endocytosis (Haj, Verveer et al. 2002), suggesting a role for PTP1B in the termination 
of the ligand-induced receptor PTK signaling. Further important substrates were 
found in PTP1B
-/-
 mouse embryonic fibroblast cells (MEFs), including p62DOK and 
p120RasGAP which are known to regulate proliferation (Dube, Cheng et al. 2004). 
The enzymatic substrates network of PTP1B is rendered more complex by the 
finding that, besides acting as an inhibitor of proliferative and metabolic signals, it 
can also have a positive signaling role in proliferation and other pathways. Indeed, 
PTP1B was shown to activate endogenous SRC by dephosphorylating the inhibitory 
tyrosine Y527 in breast and colon cancer cells (Bjorge, Pang et al. 2000; Arias-
Romero, Saha et al. 2009). This activation was shown to promote growth and invasion 
of cancer cells suggesting a role for PTP1B as an oncogene. 
Although increasing progresses have been made to characterize the substrates 
of PTP1B, the network of interactions and enzymatic substrates that have been 
discovered are not sufficient to fully explain the physiological phenotype observed by 
modulating PTP1B levels in vitro and in vivo. This is rendered difficult because 
PTP1B was shown to function in a tissue specific manner and because of its dual role 
in signaling, acting as signal activator or as signal inhibitor. Therefore, further studies 
are needed to delineate the signaling pathways regulated by PTP1B.  
  
 
 
Introduction 
[Type the date] 
 
 26 
3.11 PTP1B and oncogenesis: tumor suppressor or oncogene? 
 
Genetic analysis of human and mouse models of cancer revealed no loss of function 
or gene silencing of PTP1B gene. However, several evidences support the notion that 
PTP1B is a negative regulator of cellular growth. PTP1B plays an important role in 
dephosphorylating receptor PTKs known to be involved in oncogenesis. Studies in 
immortalized fibroblast revealed that exogenous expression of PTP1B prevents 
transformation by v-src, v-ras, v-crk, and Bcr-Abl (Woodford-Thomas, Rhodes et al. 
1992; LaMontagne, Hannon et al. 1998; Liu, Sells et al. 1998). Furthermore, PTP1B 
was shown to promote apoptosis by increasing IRE1-mediated endoplasmic reticulum 
stress signaling (Gu, Nguyen et al. 2004), by downregulating pro-survival receptor 
PTKs (Gonzalez-Rodriguez, Escribano et al. 2007) or by facilitating the activity of 
Caspase 8/9 (Akasaki, Liu et al. 2006; Sangwan, Paliouras et al. 2006). All these 
observations suggest PTP1B as a tumor suppressor. The detection of high PTP1B 
expression in human tumors, most notably breast and ovarian cancers (Wiener, 
Hurteau et al. 1994; Wiener, Kerns et al. 1994), suggested a role for this protein in 
tumorigenesis. A breast cancer study suggested overexpression of PTP1B in 38% of 
the cases and that the expression of PTP1B positively correlated with HER2 
expression, a well known oncogenic PTK frequently amplified in a subset of breast 
tumors (Wiener, Kerns et al. 1994). This correlation suggests a collaboration between 
these two proteins in tumorigenesis. Indeed, two independent groups discovered that a 
deficiency of PTP1B in a HER2/Neu-evoked breast cancer mouse model delayed 
tumor onset (Bentires-Alj and Neel 2007; Julien, Dube et al. 2007). Recent studies in 
our lab demonstrated that deletion of PTP1B specifically in the mammary epithelium 
delays HER2/NeuNT-induced breast cancer (Balavenkatraman, Aceto et al. 2011). 
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However, no effects on tumor progression were observed when the deletion of PTP1B 
occurred after the development of the breast cancer. These observations suggest a role 
for PTP1B in tumor onset but not in tumor growth progression, making PTP1B a 
therapeutic target for tumor prevention but not for treatment of advanced tumors.  
In conclusion, PTP1B can act both as tumor suppressor and as oncogene depending 
on the substrate involved and the cellular context (Lessard, Stuible et al. 2010). The 
dual role of PTP1B in cancer highlights the need of a better understanding of its 
function prior to use PTP1B inhibitors to treat cancer. 
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4. RATIONALE OF THE WORK 
 
The mouse mammary gland is a heterogeneous organ that undergoes most of its 
development after birth and goes through repeated cycles of proliferation, 
differentiation and apoptosis with every pregnancy. Although many studies were 
performed to elucidate the mechanism of mammary gland development and 
differentiation, the molecular and cellular events are not completely understood. 
Elucidating the mechanisms regulating normal mammary gland development 
is of major importance to better understand the development of diseases like breast 
cancer. Recently, PTP1B has received major interest due to the discovery of its 
oncogenic role in breast cancer development, suggesting PTP1B as a new target for 
the treatment of breast cancer. This work aims at understanding the role of PTP1B in 
mammary gland development and differentiation. We addressed this question by 
studying: 
a) The role of PTP1B in cell fate commitment: 
Recent studies demonstrated the existence of a mammary stem cell hierarchy, 
which is tightly regulated in each stage of mammary gland development to 
guarantee the correct formation of a functional mammary gland. Several 
transcription factors were shown to play an important role in the regulation of the 
commitment of mammary stem cells to progenitor cells and finally into 
differentiated epithelial cells. One of these is STAT5, shown to be a downstream 
target of PTP1B in vitro, raising the question whether PTP1B also plays a role in 
cell fate commitment.  
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b) The role of PTP1B in mammary gland development: 
Previous in vitro studies suggested a role for PTP1B in normal mammary gland 
development by regulating the prolactin-mediated activation of STAT5, a key 
regulator of mammary gland development and differentiation. While informative, 
these findings were based on knockdown experiments in breast cancer cell lines, 
which may not accurately reflect the in vivo situation. We therefore, used a 
genetically ablated PTP1B mouse model to gain a deeper knowledge of the role 
PTP1B plays in mammary gland development and to define the mechanism 
regulated by this phosphatase. 
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5. Results 
Research article published in Development: 
 
 
Protein tyrosine phosphatase 1B restrains mammary 
alveologenesis and secretory differentiation 
Emanuela S. Milani, Heike Brinkhaus, Regula Dueggeli, Ina Klebba, Urs Mueller, 
Michael Stadler, Hubertus Kohler, Matthew J. Smalley and Mohamed Bentires-Alj 
 
Tyrosine phosphorylation plays a fundamental role in mammary gland development. 
However, the role of specific tyrosine phosphatases in controlling mammary cell fate 
remains ill defined. We have identified protein tyrosine phosphatase 1B (PTP1B) as 
an essential regulator of alveologenesis and lactogenesis. PTP1B depletion increased 
the number of luminal mammary progenitors in nulliparous mice, leading to enhanced 
alveoli formation upon pregnancy. Mechanistically, Ptp1b deletion enhanced the 
expression of progesterone receptor and phosphorylation of Stat5, two key regulators 
of alveologenesis. Furthermore, glands from Ptp1b knockout mice exhibited increased 
expression of milk proteins during pregnancy due to enhanced Stat5 activation. These 
findings reveal that PTP1B constrains the number of mammary progenitors and thus 
prevents inappropriate onset of alveologenesis in early pregnancy. Moreover, PTP1B 
restrains the expression of milk proteins during pregnancy and thus prevents 
premature lactogenesis. Our work has implications for breast tumorigenesis 
because Ptp1b deletion has been shown to prevent or delay the onset of mammary 
tumors. 
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INTRODUCTION
The epithelium of rodent and human mammary glands is
hierarchically organized, encompassing cells at various
differentiation stages (Stingl et al., 2006b; LaBarge et al., 2007;
Visvader, 2009; Visvader and Smith, 2011). The results of serial
transplantation of mammary gland fragments into cleared mouse
mammary fat pad suggested the existence of mammary stem cells
(Deome et al., 1959; Faulkin and Deome, 1960). Direct evidence was
provided by the finding that serial transplantation of fragments from
mouse mammary tumor virus-infected mammary glands yields
clonal outgrowths with the same viral insertion site through five
transplant generations (Kordon and Smith, 1998; Bruno and Smith,
2011). Other studies have used cell surface markers to enrich for, and
isolate, mammary stem cells, progenitor cells, and more
differentiated luminal and myoepithelial cells (Shackleton et al.,
2006; Sleeman et al., 2006; Stingl et al., 2006a; Asselin-Labat et al.,
2007; Regan et al., 2011). Notably, these cell subpopulations display
different functional attributes: mammary stem cells [MaSCs, also
called mammary repopulating units (MRUs)] are able to repopulate
a cleared mammary fat pad. Progenitor cells display a high capacity
for colony formation and proliferation in vitro. By contrast,
terminally differentiated cells are not able to repopulate the
mammary gland or to form colonies in vitro (Shackleton et al., 2006;
Sleeman et al., 2006; Stingl et al., 2006a; Asselin-Labat et al., 2007).
Recent lineage-tracing studies have questioned the existence of adult
multipotent MaSCs and have instead suggested the existence of
unipotent luminal and myoepithelial progenitor cells in the adult
gland (Van Keymeulen et al., 2011).
The mammary gland undergoes functional differentiation
during pregnancy. In the early stages, epithelial cells undergo
extensive proliferation and form alveoli (alveologenesis)
(Brisken, 2002), while in later stages of pregnancy alveolar cells
secrete milk proteins (lactogenesis) (Neville et al., 2002;
Hennighausen and Robinson, 2005; Brisken and Rajaram, 2006).
Progesterone induces the expansion of MaSCs and the formation
of mammary alveoli via activation of the Rankl (Tnfsf11)
pathway, which in turn elicits the proliferation of epithelial cells
(Asselin-Labat et al., 2010; Joshi et al., 2010). Prolactin (Prl)
controls alveologenesis and lactogenesis via binding to its
receptor [prolactin receptor (Prl-R; Prlr)] and activation of the
Jak2/Stat5 pathway. Activated Stat5 translocates to the nucleus
and induces expression of its target genes (e.g. milk proteins)
(Gouilleux et al., 1994; Wartmann et al., 1996; Groner, 2002).
Although Prl-R, Jak2 and Stat5 are regulated by tyrosine
phosphorylation, little is known about how protein tyrosine
phosphatases regulate this pathway and affect breast cell fate and
differentiation in vivo.
Protein tyrosine phosphatase 1B (PTP1B; also known as Ptpn1),
a ubiquitously expressed phosphatase, is an established negative
regulator of insulin and leptin signaling and a leading target for the
treatment of diabetes and obesity (Elchebly et al., 1999; Klaman et
al., 2000). PTP1B is also involved in breast cancer. Whole-body or
mammary-specific deletion of Ptp1b delays or prevents mammary
tumor onset evoked by Her2 (also known as Neu and Erbb2)
(Bentires-Alj and Neel, 2007; Julien et al., 2007; Balavenkatraman
et al., 2011).
In contrast to its well-studied involvement in metabolism and
cancer, the role of PTP1B in breast development remains
unclear. Early in vitro studies suggested that both Jak2 and Stat5
are PTP1B substrates (Myers et al., 2001; Aoki and Matsuda,
2002). In the present study, we asked whether PTP1B controls
mammary cell fate commitment and/or alveologenesis and
lactogenesis in vivo. Using Ptp1b knockout mice, we have found
that PTP1B depletion increases the number of mammary
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SUMMARY
Tyrosine phosphorylation plays a fundamental role in mammary gland development. However, the role of specific tyrosine
phosphatases in controlling mammary cell fate remains ill defined. We have identified protein tyrosine phosphatase 1B (PTP1B) as
an essential regulator of alveologenesis and lactogenesis. PTP1B depletion increased the number of luminal mammary progenitors
in nulliparous mice, leading to enhanced alveoli formation upon pregnancy. Mechanistically, Ptp1b deletion enhanced the expression
of progesterone receptor and phosphorylation of Stat5, two key regulators of alveologenesis. Furthermore, glands from Ptp1b
knockout mice exhibited increased expression of milk proteins during pregnancy due to enhanced Stat5 activation. These findings
reveal that PTP1B constrains the number of mammary progenitors and thus prevents inappropriate onset of alveologenesis in early
pregnancy. Moreover, PTP1B restrains the expression of milk proteins during pregnancy and thus prevents premature lactogenesis.
Our work has implications for breast tumorigenesis because Ptp1b deletion has been shown to prevent or delay the onset of
mammary tumors.
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progenitor cells in nulliparous mice, induces precocious
formation of alveoli, and enhances the expression of milk
proteins during pregnancy.
MATERIALS AND METHODS
Mice
All animal experiments were performed according to Swiss guidelines
governing animal experimentation and were approved by the Swiss
veterinary authorities. Ptp1b–/– mice (Klaman et al., 2000) were
backcrossed to an FVB background for at least seven generations. Twelve-
week-old female mice were mated and pregnancy scored by the
observation of a vaginal plug and confirmed by the presence of fertilized
eggs or embryos when mammary glands were collected at pregnancy days
3, 7 or 10. Mammary glands from nulliparous mice were collected when
mice were in estrus, as determined by a vaginal plug after an overnight
mating with a male.
Whole-mounts and histological analysis
For whole-mounts and histology, inguinal and thoracic mammary glands
were dissected at the indicated time points. Following fixation with
methacarn solution for 4 hours, tissues were hydrated, stained with
Carmine Alum, and cleared with xylene. After analysis, the tissues were
processed for paraffin sectioning and stained with Hematoxylin and Eosin
(H&E).
Immunohistochemistry and immunofluorescence
Immunohistochemistry was performed on methacarn-fixed or 4%
paraformaldehyde (PFA)-fixed, paraffin-embedded tissue sections using the
following antibodies: Ki67 (Lab Vision), rabbit anti-milk serum (Marte et
al., 1995), pStat5 (Cell Signaling Technology), Stat5 (Santa Cruz
Biotechnology), estrogen receptor (ER; Esr1) (Santa Cruz Biotechnology)
and progesterone receptor (PR; Pgr) (Thermo Scientific).
Immunohistochemistry was carried out with the Discovery XT Staining
Module (Ventana Medical Systems), except for ER and PR
immunohistochemistry, which were performed manually. All sections were
counterstained with Hematoxylin (J.T.Baker). Quantification of pStat5, PR
and ER was performed by counting cells from at least 20 fields at a
magnification of 20 and at least 2000 nuclei per sample. The number of
positive cells was expressed as a percentage of the total number of
Hematoxylin-stained cells. Quantification of epithelial density and
proliferation index were performed on mammary gland sections stained
with periodic acid Schiff (Ventana Medical Systems) and Hematoxylin, and
scanned with Miramax Scan (Carl Zeiss). For epithelial density, the area
covered by epithelial cells (excluding lumen and blood vessels) was
measured and the ratio of epithelial area over total organ area was
calculated using Definiens software as described (Stoelzle et al., 2009). The
same protocol was followed for the proliferation index using the area
covered by Ki67-positive epithelial cells over total area of epithelial cells.
At least three mice per genotype were scanned for each developmental
stage.
Immunofluorescence was performed on 4% PFA-fixed, paraffin-
embedded tissue sections stained with Rankl; tissues were then incubated
with Alexa Fluor 546 anti-goat IgG (Molecular Probes, Invitrogen), stained
with DAPI (Boehringer Mannheim), mounted in ProLong Gold antifade
reagent (Invitrogen), and analyzed with an LSM 700 scanning head and
Zen 2010 software (Carl Zeiss).
Crystal Violet staining was performed on cells grown in 24-well BD
Primaria plates (BD Biosciences). The numbers and sizes of Crystal Violet-
stained colonies per well were quantified using ImagePro software (Media
Cybernetics). Three wells per genotype were examined in four independent
experiments.
Immunoblotting
Protein lysates were extracted from inguinal mammary glands using
RIPA buffer [50 mM Tris pH 7.5, 1% Triton X-100, 150 mM NaCl,
0.5% sodium deoxycholate, 0.1% SDS, 5 mM EGTA, 10 mM NaF,
2 mM sodium orthovanadate, 2 mM PMSF and protease inhibitor
cocktail (Pierce)]. Proteins (50 g) were resolved on SDS-PAGE (Bio-
Rad) and transferred to a PVDF membrane (Immobilon-FL, Millipore).
Membranes were blocked in PBS with 5% skimmed milk powder and
incubated with PTP1B (Klaman et al., 2000), pStat5 (Cell Signaling) and
Stat5a (Transduction Laboratories) antibodies. Antibody binding was
visualized by incubation of secondary antibodies comprising Alexa
Fluor 680 anti-mouse IgG, Alexa Fluor 680 anti-rabbit IgG (Molecular
Probes, Invitrogen), IRDye 800 anti-mouse IgG and IRDye 800 anti-
rabbit IgG (Rockland), and examined with an Odyssey infrared imaging
system (Li-Cor Bioscience).
Real-time PCR
Total RNA was isolated from frozen mammary glands using TRIzol
reagent (Invitrogen) according to the manufacturer’s instructions and then
treated with the TURBO-DNase Kit (Applied Biosystems). cDNA
synthesis was performed using the Thermoscript RT-PCR system
(Invitrogen). Real-time PCR was performed on 30-60 ng cDNA using the
TaqMan Gene Expression Assay (Applied Biosystems) for Wap
(Mm00839913_m1), -casein (Mm00839664_m1), cytokeratin 18
(Mm01601702_g1), Rankl (Mm00441906_m1), Pr (Mm00435628_m1),
Er (Mm00433149_m1) and Gapdh (Rodent Gapdh Control Reagents VIC
Probe, Applied Biosystems) on an ABI Prism 7000 (Applied Biosystems)
according to the manufacturer’s instructions.
Mammary cell preparation, cell sorting and cell culture
Inguinal mammary glands were dissected from 10-week-old virgin females
or pregnant mice at gestation day 10, mechanically disaggregated, and
digested with collagenase (Sigma) and trypsin (Sigma) for 1 hour at 37°C
(Sleeman et al., 2006). The resulting organoids were processed to single-
cell suspensions by digestion with HyQTase (HyClone) for 10-15 minutes
at 37°C and filtered through a 40-m cell strainer (Falcon). Cells were
stained as previously described (Sleeman et al., 2006) with the following
antibodies: FITC-CD24, PE-CD49f (Itga6), PE-Cy7-CD45 (Ptprc)
(Pharmingen), APC-Sca1 (Ly6a), biotinylated-CD61 (Itgb3) (Biolegend)
and streptavidin-PE-Cy5.5 (eBioscience). FACS analysis and cell sorting
were carried out on a MoFlo cell sorter (Beckman Coulter).
Colony-forming assays were performed by plating freshly sorted cells
(500 cells) on irradiated 3T3-L1 feeder cells in Multiwell BD Primaria
plates for 7 days in DMEM/Ham’s F12 mix (Invitrogen) with 10% fetal
calf serum, 100 IU/ml penicillin, 100 g/ml streptomycin (Invitrogen), 5
g/ml bovine pancreatic insulin (Sigma, cell culture tested solution) and
10 ng/ml cholera toxin (Sigma). Aldefluor assay was performed according
to the manufacturer’s instructions (Stemcell Technologies).
Hormone treatment
Six-week-old female mice were ovariectomized and treated 10 days later
every 24 hours by subcutaneous injection of 17-estradiol (Sigma; 4 ng/g
body weight) in corn oil (Sigma) and sacrificed 48 hours later. For
treatment with estrogen and progesterone, ovariectomized mice were
injected with 17-estradiol and 48 hours later injected with 17-estradiol
plus progesterone (Sigma; 100 g/g body weight) daily for 72 hours.
Chemicals
NVP-BSK805 (Novartis, Switzerland) was freshly prepared in NMP/PEG
300/Solutol HS15 (5%/80%/15%). Twelve-week-old mice were treated
every 24 hours by oral gavage (120 mg/kg body weight) for 5 consecutive
days. Glands were collected and fixed 4 hours after the final treatment.
Microarray analysis
RNA was isolated from three biological replicates per condition using
the RNeasy Plus Mini Kit (Qiagen) according to the manufacturer’s
instructions. RNA concentration was measured using a NanoDrop 1000
and the quality of the RNA assessed using the Agilent 2100 bioanalyzer
and RNA Nano Chip. Aliquots (100 ng) of extracted total RNA were
amplified using the Ambion WT Expression Kit and the resulting sense-
strand cDNA was fragmented and labeled using the Affymetrix
GeneChip WT Terminal Labeling Kit. Affymetrix GeneChip arrays were
hybridized following the GeneChip Whole Transcript (WT) Sense Target
Labeling Assay Manual (Affymetrix) with a hybridization time of 16
hours. The Affymetrix Fluidics protocol FS450_0007 was used for
washing. Scanning was performed with Affymetrix GCC Scan Control
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version 3.0.0.1214 on a GeneChip Scanner 3000 with autoloader. Probe
sets were summarized and probeset level values normalized with the
justRMA() function from the R (version 2.12.0)/Bioconductor (version
2.6) package affy using the CDF environment MoGene-1_0-st-v1.r3.cdf
(as provided by Bioconductor). Differentially expressed genes were
identified using the R package limma (Gentleman et al., 2004) and by
selecting genes with a minimum absolute log2 fold change of 1.5 and
P<0.05, using the method of Benjamini and Hochberg for multiple
testing correction. Microarray data are available at GEO under accession
number GSE41768.
Statistical analysis
Statistical significance was determined by two-tailed Student’s t-test. For
FACS analysis, a paired two-tailed Student’s t-test was performed.
RESULTS
Ptp1b deletion accelerates alveologenesis
Tyrosine phosphorylation plays an important role in mammary
gland alveologenesis. To determine whether PTP1B regulates this
process, we analyzed mammary glands of PTP1B-deficient and
wild-type (WT) female mice at different developmental stages.
Whole-mounts and histological analysis showed significant
changes in the structure of PTP1B-depleted compared with control
glands (Fig. 1A). In nulliparous mice at estrus, H&E and Ki67
staining revealed a twofold increase in epithelial cell density and
threefold more Ki67-positive cells in glands lacking PTP1B than
in WT glands (Fig. 1B-D). During early stages of pregnancy,
Ptp1b–/– glands showed an overall increase in the number of
epithelial cells and alveolar structures (Fig. 1B,C). These results
demonstrate that PTP1B constrains cell proliferation and
alveologenesis during estrus and early pregnancy.
Increased progenitor cell number in mammary
glands from Ptp1b–/– mice
To test whether the enhanced epithelial density found in PTP1B-
deficient mice is a consequence of an increase in the
stem/progenitor cell subpopulations, we characterized mammary
epithelial cells (MECs) from Ptp1b+/+ and Ptp1b–/– mice
phenotypically using Sca1, CD24 and CD49f markers (Sleeman et
al., 2006; Stingl et al., 2006a), which have been shown to enrich
for MaSCs (CD24lo Sca1– CD49f+), luminal progenitor cells
(CD24hi CD61+), more differentiated luminal cells (CD24hi CD61–)
and myoepithelial cells (CD24lo CD49flo) (Asselin-Labat et al.,
2007; Sleeman et al., 2007). We found no significant differences in
the proportion of MECs bearing the stem cell phenotype (CD24lo
Sca1– CD49f+) or in the proportions of total luminal epithelial cells
(CD24hi Sca1– and CD24hi Sca1+) in Ptp1b–/– versus Ptp1b+/+ mice
(Fig. 2A; supplementary material Fig. S1A). Limiting dilution
transplantation experiments showed no difference in the capacities
of Ptp1b–/– and Ptp1b+/+ MECs to repopulate the mammary gland
and, thus, that Ptp1b ablation does not alter the properties of
mammary repopulating cells (supplementary material Fig. S1B).
We then investigated whether Ptp1b deletion alters mammary
colony-forming capacity (Stingl et al., 2006a). Freshly isolated
MECs from Ptp1b+/+ and Ptp1b–/– glands were cultured on feeder
cells and the number of colonies quantified. Ptp1b–/– MECs formed
approximately twice as many colonies as Ptp1b+/+ MECs, which
suggested an increase in progenitor cells in glands lacking PTP1B
(Fig. 2B). Furthermore, the colonies formed by Ptp1b–/– MECs
were larger (Fig. 2B), consistent with our results showing increased
proliferation in glands from Ptp1b–/– compared with Ptp1b+/+ mice
(Fig. 1D). The increase in progenitor cell number was further tested
by FACS analysis for CD61, an epithelial progenitor marker
(Asselin-Labat et al., 2007). We found a significant increase in the
CD24hi CD61+ population in Ptp1b–/– MECs compared with
Ptp1b+/+ MECs (29.63% CD24hi CD61+ cells in Ptp1b–/– MECs
versus 19.86% in Ptp1b+/+ MECs) (Fig. 2C).
Several studies have suggested that high aldehyde
dehydrogenase (ALDH) activity is a property of stem and/or
progenitor cells in human and mouse mammary tissues (Ginestier
et al., 2007; Cohn et al., 2010; Eirew et al., 2012). Using the
Aldefluor assay, we found a higher ALDH activity in MECs from
Ptp1b–/– than Ptp1b+/+ mice (supplementary material Fig. S1C),
further supporting an increase in the proportion of mammary
progenitor cells in PTP1B-deficient glands. Together, these results
show that PTP1B restrains the number of mammary progenitor
cells in nulliparous mice.
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Fig. 1. Alveolar development is accelerated in PTP1B-deficient
mammary glands. (A) Whole-mounts of Ptp1b–/– mammary tissues
showing precocious alveolar formation compared with Ptp1b+/+ mice.
Boxed regions are magnified in images on the right. (B) H&E-stained
histological sections of Ptp1b+/+ and Ptp1b–/– mammary tissues. (C) The
percentages of epithelial cells in Ptp1b+/+ and Ptp1b–/– glands from
nulliparous mice at estrus. (D) (Left) Ki67-stained histological sections.
(Right) Proliferating (Ki67+) cells as a percentage of total epithelial cells
per gland. Pregnancy day 0 (P0) refers to nulliparous mice at estrus.
Error bars indicate mean ± s.e.m.; *P<0.05 by Student’s t-test; C,D,
n=4. Scale bars: 1 mm in A; 100 m in B,D.
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PTP1B negatively regulates ER activity
To investigate the molecular mediators of the observed increase
in epithelial density and mammary progenitors in mammary
glands from Ptp1b–/– mice, we performed gene expression
profiling of Ptp1b–/– and Ptp1b+/+ glands from mice at estrus.
The absence of PTP1B increased the expression of several
components of the cell cycle machinery: including cyclin B2,
cyclin A2, cyclin-dependent kinase 1 and topoisomerase 2A
(Fig. 3A; supplementary material Fig. S2A, Table S1). These
results, combined with the increased proliferation observed by
immunohistochemistry (Fig. 1D), support a role for PTP1B in
the regulation of epithelial cell proliferation.
Further, analysis of the expression profiles of Ptp1b–/– and
Ptp1b+/+ glands revealed increased expression of several estrogen-
responsive genes (supplementary material Fig. S2A): Pr,
amphiregulin, Expi (Wfdc18), Egr2 and c-Myb. Furthermore,
quantitative RT-PCR and immunohistochemistry analysis revealed
an increase in PR expression in glands lacking PTP1B (Fig. 3B,C).
Similarly, we found increased expression of Rankl, an established
downstream target of PR (Fata et al., 2000; Beleut et al., 2010), in
glands deficient in PTP1B (Fig. 3B; supplementary material Fig.
S2B). These data suggest that PR-induced expression of Rankl
might account for the increased number of MECs observed in
glands from Ptp1b–/– mice.
We then tested whether overexpression of ER and/or estrogen
accounts for the increased transcription of ER targets in glands from
Ptp1b–/– mice, but found no difference in ER expression between
Ptp1b–/– and Ptp1b+/+ glands (Fig. 3B,C) and no difference in plasma
levels of estrogen between Ptp1b–/– and Ptp1b+/+ mice at estrus
(supplementary material Fig. S3A). Further analysis showed no
differences in the plasma levels of progesterone in Ptp1b–/– and
Ptp1b+/+ mice (supplementary material Fig. S3A). Thus, Ptp1b
deletion appears to increase mammary cell proliferation by
enhancing the responsiveness of the mammary gland to normal
levels of circulating estrogen and progesterone. To test this
possibility directly, we assessed the effects of 17-estradiol treatment
alone or in combination with progesterone on Ptp1b–/– and Ptp1b+/+
mice that were previously depleted of endogenous steroid hormones
by ovariectomy. Treatment with 17-estradiol for 48 hours increased
the expression of PR in glands from Ptp1b–/– ovariectomized mice
compared with ovariectomized WT littermates (Fig. 3D). These data
show that Ptp1b deletion increases ER activity in nulliparous glands.
Furthermore, treatment of Ptp1b–/– and Ptp1b+/+ mice with 17-
estradiol and progesterone for 72 hours resulted in enhanced
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Fig. 2. PTP1B depletion increases the
proportion of mammary progenitors.
(A) (Top row, left) Flow cytometry dot plots of
mammary epithelial cells (MECs) from nulliparous
mice at estrus. Luminal cells: CD24hi Sca1+ and
CD24hi Sca1–. Basal cells: CD24lo Sca1–. (Top
row, right) The percentages of luminal and basal
cell subpopulations of MECs from Ptp1b+/+ and
Ptp1b–/– nulliparous mice at estrus. (Bottom row,
left) Dot plots of myoepithelial (CD24lo Sca1–
CD49f–) and mammary stem cell (MaSC) (CD24lo
Sca1– CD49f+) populations. (Bottom row, right)
The percentages of myoepithelial and MaSC
populations of Ptp1b+/+ and Ptp1b–/– glands from
nulliparous mice at estrus. Error bars indicate
mean ± s.e.m. (n=6). (B) (Left) Colony formation
assay of MECs from nulliparous mice at estrus.
Scale bar: 1 mm. (Right) The number of Ptp1b+/+
and Ptp1b–/– colonies. Small refers to colonies
<8000 m2 and big to colonies >8000 m2
(n=4, **P<0.01 by Student’s t-test). (C) (Left)
Flow cytometry dot plots of luminal cells (CD24hi
Sca1+ and CD24hi Sca1–) of MECs from
nulliparous mice at estrus stained for the
progenitor marker CD61. (Right) The
percentages of CD61+ and CD61– populations of
Ptp1b–/– and Ptp1b+/+ MECs. Error bars indicate
mean ± s.e.m. (n=4, **P<0.01 by paired two-
tailed Student’s t-test).
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expression of Rankl and proliferation of Ptp1b–/– epithelial cells
compared with WT (Fig. 3E; supplementary material Fig. S2B).
Thus, PTP1B restrains epithelial cell proliferation by negatively
regulating ER activity and PR expression.
PTP1B depletion increases Stat5 phosphorylation
Genetic depletion of Stat5 revealed that this transcription factor
enhances the proliferation of epithelial cells in response to
estrogen and progesterone stimuli, increases the number of
mammary luminal progenitor cells, and promotes alveologenesis
(Miyoshi et al., 2001; Cui et al., 2004; Yamaji et al., 2009). The
in vitro data suggesting Stat5 as a potential PTP1B substrate
(Aoki and Matsuda, 2002) raise the possibility that Stat5 is
hyperactivated in glands lacking PTP1B. To test this, we stained
control and Ptp1b knockout glands for Stat5 and phosphorylated
Stat5 (pStat5) and found a dramatic increase in pStat5 in the
absence of PTP1B (Fig. 4A). We then tested whether Jak2/Stat5
inhibition blocks the increased epithelial cell proliferation
observed in Ptp1b–/– glands. Treatment of Ptp1b–/– and Ptp1b+/+
mice with NVP-BSK805 [a selective Jak2 inhibitor that results
in Stat5 dephosphorylation (Baffert et al., 2010)] inhibited Stat5
phosphorylation and, notably, significantly reduced proliferation
in Ptp1b–/– glands (Fig. 4B).
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Fig. 3. Absence of PTP1B increases the expression of cell cycle
and estrogen-responsive genes. (A) Fold changes in Cdk1 and
Ccnb2 mRNA as assessed by quantitative real-time PCR. (B) Er, Pr and
Rankl mRNA fold changes as assessed by quantitative real-time PCR. 
(C) (Left) ER- and PR-stained sections of mammary glands from
nulliparous mice at estrus. (Right) The percentages of PR- and ER-
positive epithelial cells. (D) (Top) Mammary glands from ovariectomized
(OVX) mice treated (or otherwise) with 17-estradiol (+E) for 48 hours
and stained for PR. (Bottom) The percentages of PR-positive epithelial
cells in 17-estradiol-treated glands (22 images from two mice per
genotype were quantified). (E) (Top) Mammary glands from
ovariectomized mice treated with 17-estradiol alone (+E) or together
with progesterone (E+P) for 72 hours and stained for Ki67. (Bottom)
The percentages of Ki67-positive epithelial cells in the 17-estradiol
plus progesterone-treated glands (30 images from four mice per
genotype were quantified). Error bars indicate mean ± s.e.m.; *P<0.05,
**P<0.01 by Student’s t-test; A-C, n=3. Scale bars: 50 m.
Fig. 4. Absence of PTP1B increases Stat5 phosphorylation. (A)
(Top) Mammary gland sections from nulliparous mice at estrus stained
for pStat5 and Stat5. (Bottom) The percentage of cells positive for
nuclear pStat5. Error bars indicate mean ± s.e.m.; n=4; **P<0.01 by
Student’s t-test. (B) Mammary gland sections from NVP-BSK805-treated
mice stained for pStat5, Stat5 or Ki67. Scale bars: 50 m.
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We next investigated whether overexpression of Prl and/or Prl-
R or hyperphosphorylation of Jak2 accounts for the increased
pStat5 in glands from Ptp1b–/– mice. We found no difference in the
plasma levels of Prl, in Prl-R expression or in Jak2 expression 
and phosphorylation between Ptp1b–/– and Ptp1b+/+ glands
(supplementary material Fig. S3A-D). This suggests that PTP1B
acts via the Stat5 pathway in constraining epithelial cell
proliferation.
PTP1B depletion accelerates mammary gland
differentiation during pregnancy
We next assessed the consequences of Ptp1b deletion on mammary
gland development at later stages of pregnancy. Similar to the
phenotype at pregnancy day 3 (Fig. 1A,B), whole-mounts and
H&E staining of glands showed that the absence of PTP1B also
results in the increased formation of alveolar structures at
pregnancy days 7 and 10 (Fig. 5A-C).
FACS analysis of MECs isolated from Ptp1b+/+ and Ptp1b–/–
mice at pregnancy day 10 showed an increase in the luminal
CD24hi Sca1– population, which is enriched in milk-expressing
cells (Sleeman et al., 2006). No changes were observed in the other
subpopulations (Fig. 5D). Furthermore, histological analysis
revealed that the alveolar structures in Ptp1b–/– but not Ptp1b+/+
glands were precociously distended, displayed lipid droplets and
expressed milk proteins, which are all characteristics of
differentiated alveoli (Fig. 5A,B, Fig. 6A). Given the higher
number of alveoli in glands lacking PTP1B, the observed increase
in milk protein expression might be caused by enhanced expression
and/or by an increase in the number of milk-producing cells. To
distinguish these possibilities, we assessed expression of the genes
encoding the early pregnancy milk protein -casein and the late
pregnancy milk protein whey acidic protein (Wap), normalized to
the expression of epithelial markers cytokeratin 8 and 18 in glands
from control and Ptp1b–/– mice. PTP1B-depleted alveoli not only
expressed milk proteins precociously but also expressed a higher
level of milk proteins per cell. PTP1B depletion resulted in 5.5-fold
and 4.9-fold increases in the levels of -casein and Wap,
respectively (Fig. 6B; data not shown).
Next, we assessed the molecular mechanism underlying the
precocious lactogenesis seen in Ptp1b–/– glands. Immunoblotting
revealed increased phosphorylation of Stat5, a well-established
inducer of milk protein expression during pregnancy (Wakao et al.,
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Fig. 5. Precocious secretory differentiation in
PTP1B-deficient mammary glands. (A) Whole-
mounts of Ptp1b+/+ and Ptp1b–/– mammary tissues at
pregnancy days 7 and 10. Boxed regions are magnified
in images on the right. (B) H&E-stained histological
sections of Ptp1b+/+ and Ptp1b–/– mammary tissues at
pregnancy days 7 and 10. The arrow points to lipid
droplets. (C) The percentages of alveolar cells in
Ptp1b+/+ and Ptp1b–/– glands at pregnancy days 7 and
10. (D) (Top row) Dot plots (left) and percentages (right)
of luminal (CD24hi Sca1+ and CD24hi Sca1–) and basal
(CD24lo Sca1–) cell populations from Ptp1b–/– and
Ptp1b+/+ glands at pregnancy day 10. (Bottom row) Dot
plots (left) and percentages (right) of myoepithelial
(CD24lo Sca1– CD49f–) and stem cell (CD24lo Sca1–
CD49f+) populations. Error bars indicate mean ± s.e.m.;
*P<0.05 by Student’s t-test; C, n=4; D, n=3. Scale bars:
1 mm in A; 100 m in B.
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1994; Liu et al., 1997), in PTP1B-deficient glands compared with
controls (Fig. 6C). To exclude the possibility that the observed
changes in pStat5 were due to changes in the stroma and not in
epithelial cells, we performed immunostaining against pStat5. We
found that pStat5 in epithelial cells of glands lacking PTP1B was
markedly increased (Fig. 6D). We then tested whether Jak2
expression and/or phosphorylation is altered in glands lacking PTP1B
and found no difference in pJak2 between Ptp1b–/– and Ptp1b+/+
glands at pregnancy day 10 (supplementary material Fig. S3C,D).
To investigate whether Ptp1b deletion affects involution, we
analyzed glands from Ptp1b–/– and Ptp1b+/+ mice 5 days after
cessation of suckling and observed no differences (supplementary
material Fig. S3E).
These data show that PTP1B depletion precociously increases
Stat5 phosphorylation, thus triggering the expression of milk
proteins. This suggests that PTP1B expression constrains
lactogenesis during pregnancy.
DISCUSSION
Tight regulation of mammary alveologenesis and lactogenesis is
fundamental for lactating species. In this study, we have shown that
the tyrosine phosphatase PTP1B constrains these important
processes. Alveologenesis is a developmental program
characterized by the expansion and differentiation of mammary
progenitor cells into alveolar cells. Loss of PTP1B increases the
number of progenitor cells in nulliparous mice. This enhances the
pool of cells able to generate alveolar structures and, thus, results
in the increased alveolar density observed in Ptp1b–/– glands during
early pregnancy.
Several factors influence mammary gland alveologenesis.
Mechanistically, we found that lack of PTP1B induces the
expression of several estrogen-responsive genes in nulliparous
glands, including Pr and its downstream target Rankl. PR plays a
key role in epithelial cell proliferation and alveolar formation
during early pregnancy (Lydon et al., 1995; Brisken et al., 1998;
Mulac-Jericevic et al., 2003; Obr and Edwards, 2012). Therefore,
the precocious alveolar development observed in Ptp1b–/– glands
might be mediated by the overexpression and activation of PR,
which then precociously initiates alveologenesis.
Estrogen and progesterone have been shown to regulate the
number and/or activity of MaSCs via a paracrine mechanism
involving the Rank and Wnt pathways (Asselin-Labat et al., 2010;
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Fig. 6. Activation of Stat5 induces
precocious lactogenesis in Ptp1b–/– glands.
(A) (Left) Mammary gland sections stained for
expression of total milk proteins. (Right) Milk
protein-expressing alveoli as a percentage of
total alveoli per gland. (B) Fold changes in -
casein and Wap mRNA from mice as assessed
by quantitative real-time PCR. P0, nulliparous
mice at estrus; P7 and P10, pregnancy day 7
and pregnancy day 10. (C) Immunoblots of
lysates from glands as indicated (top) and the
ratio of pStat5/Stat5 (bottom). (D) Mammary
gland sections stained for Stat5 and pStat5 at
pregnancy day 10. Error bars indicate mean ±
s.e.m.; *P<0.05, **P<0.01 by Student’s t-test;
A, n=4; B,C, n=3. Scale bars: 50 m.
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Joshi et al., 2010; Axlund and Sartorius, 2012). In glands lacking
PTP1B, we observed an increase in ER and PR activity associated
with an increase in the number and activity of progenitor cells but
not of MaSCs. The discrepancy between our results and those
reported previously might be due to differences in the degrees of
ER and PR activation in the two models.
In addition to increasing PR expression, PTP1B depletion
increased the phosphorylation of Stat5, a key regulator of
mammary luminal progenitor cells and alveologenesis (Yamaji et
al., 2009), suggesting that PTP1B restrains the number of
mammary progenitor cells and regulates alveologenesis via Stat5
dephosphorylation. Stat5 has been shown to promote the
proliferation of epithelial cells in response to estrogen and
progesterone stimuli, which indicated that they act in a common
pathway (Miyoshi et al., 2001; Cui et al., 2004). Conceivably,
PTP1B depletion increases ER activity and PR expression, which
in turn activates Stat5 and leads to increased alveologenesis. In
vitro studies have demonstrated that PTP1B can directly
dephosphorylate Stat5 (Myers et al., 2001), raising an alternative
possibility that lack of PTP1B independently increases PR
expression via ER and Stat5 phosphorylation. These two
possibilities are not mutually exclusive.
But how does lack of PTP1B increase ER activity? In vitro
studies have shown that PTP1B dephosphorylates ER at tyrosine
537, a residue known to inhibit estrogen binding and to reduce
transcriptional activity of ER when phosphorylated (Arnold 
et al., 1997). These data raise the possibility that PTP1B activates
the estrogen pathway by regulating the phosphorylation of ER.
Our results also support a role for PTP1B in lactogenesis.
PTP1B depletion induces the precocious expression of milk
proteins due to an increase in Stat5 phosphorylation. Indeed, Stat5
is a well-established regulator of lactogenesis, mediating Prl-
induced milk expression (Wakao et al., 1994; Liu et al., 1997).
Taken together, our results suggest a role for PTP1B as a temporal
regulator of mammary gland development that downregulates the
progesterone and Stat5 pathway(s) and thus prevents the
inappropriate onset of alveologenesis and lactogenesis during
pregnancy.
Mammary gland development and differentiation are regulated
by a complex mechanism involving several different pathways
(Hennighausen and Robinson, 2005; Brisken and O’Malley, 2010).
We cannot exclude the possibility that PTP1B acts via other
pathways in constraining mammary gland alveologenesis and
lactogenesis. For example, PTP1B is a well-known regulator of the
insulin and leptin pathways in other organs, and mice lacking
PTP1B are insulin and leptin hypersensitive (Elchebly et al., 1999;
Klaman et al., 2000). In the light of reports of a role for insulin,
Igf1 and Igf2 in mammary gland morphogenesis (Kleinberg et al.,
2000; Brisken et al., 2002; Hovey et al., 2003; Berlato and Doppler,
2009), PTP1B might also regulate mammary gland morphogenesis
via its inhibitory effects on these pathways.
Epidemiological studies have shown that early menarche, late
menopause and late age of first pregnancy are all risk factors for
developing sporadic breast cancer (Medina, 2005). Conversely,
early full-term pregnancy (<24 years) decreases lifetime breast
cancer risk. Clearly, the hormonal milieu and breast development
cycles, possibly through changes in the differentiation state of
breast stem/progenitor cells, affect the susceptibility of the breast
to oncogenic transformation. Our finding that Ptp1b deletion
induces precocious differentiation of the mammary gland raises the
possibility that the cells of origin of Her2-evoked mammary tumors
are decreased in Ptp1b–/– mice. This would explain why deletion
of Ptp1b delays or prevents mammary tumor formation in MMTV-
NeuNT and MMTV-NDL1 mice (Bentires-Alj and Neel, 2007;
Julien et al., 2007; Balavenkatraman et al., 2011). An exploration
of this possibility is now warranted.
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5.3	
  SUPPLEMENTARY	
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Supplemental Inventory 
 
Figure S1: PTP1B depletion increases ALDH activity in mammary epithelial cells, 
related to Figure 2. 
Figure S2: Absence of PTP1B increases expression of cell cycle genes and of the PR 
target Rank-L, related to Figure 3. 
Figure S3: Absence of PTP1B does not affect plasma levels of estrogen in mice at 
estrous, related to Figure 3 
Table S1: Top affected gene o ntology ter ms PTP1 B-/- vs. PTP1 B +/+ mammary g 
lands, related to Figure 3. 
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Fig. S1. PTP1B depletion increases ALDH activity in mammary epithelial cells. (A) Representative flow cytometry 
dot plots showing the gating strategy used to isolate mammary epithelial cell subpopulations. Cells were first gated on 
the basis of forward and side scatters (FSC-A and SSC-A), followed by the exclusion of doublets and higher-order cell 
clumps using a time-of-flight approach (pulse width). Dead cells were then gated out by DAPI staining, followed by 
the exclusion of leukocytes by CD45 staining. Finally, total epithelial cells were isolated based on their CD24 and Sca1 
expression. Further isolation of MaSCs and myoepithelial cells was performed based on the expression of CD24 and 
CD49f. (B) Mammary repopulating activity of Ptp1b+/+ and Ptp1b–/– MECs. 10,000, 5000, 2000, 1000 and 500 freshly 
isolated mammary epithelial cells (MECs) from Ptp1b–/– and Ptp1b+/+ glands in estrus were injected into the cleared fat 
pad of FVB mice. The repopulation of the fat pad was scored 7 weeks after transplantation. The transplantation frequency 
analysis was performed using R and the statmod package as previously described (Shackleton et al., 2006). (C) (Left) Dot 
plot pattern of ALDH-positive cells showing an increase in ALDH activity in Ptp1b–/– MECs. (Right) The percentages of 
cells with high ALDH activity (ALDHbr) from Ptp1b+/+ and Ptp1b–/– nulliparous mice at estrus. Values represent mean ± 
s.e.m. (n=3, *P<0.05 by Student’s t-test).
48
AB
Milani et al. Supplemental  Figure S2  
PTP1B-/-PTP1B+/+
OV
X 
E 
48
h
OV
X 
E+
P
Vi
rg
in
Rank-L
Acession # Symbol descrip on
fold 
changes
p-value
Adj            
p-value
NM_010118 Egr2  early growth response 2 3.00 2.28E-06 0.0039558
NM_009704 Areg amphiregulin 2.88 9.55E-09 0.0003318
NM_007969 Expi  extracellular proteinase inhibitor 1.98 0.001761 0.0959992
NM_001081249 Vcan(cspg2) vesican 1.94 0.001344 0.0889354
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estrogen-responsive genes upregulated in PTP1B -/-
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fold 
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p-value
NM_009828 CCNA2  cyclin A2 2.46 0.0115 0.1768713
NM_011623 Topo2  topoisomerase (DNA) II alpha 2.30 0.0078 0.1592963
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NM_011121 Plk1  polo-like kinase 1 (Drosophila) 2.14 0.0126 0.1836071
NM_007659 Cdc2a (CDK1)  cell division cycle 2 homolog A (S. pombe) 2.00 0.0104 0.1712105
NM_007691 Chek1  checkpoint kinase 1 homolog (S. pombe) 1.87 0.0244 0.2270902
NM_018754 SFN  stra fin 1.62 0.0005 0.062044
NM_001081117  Mki67  an gen iden fied by monoclonal Ab Ki 67 1.84 0.0418 0.2758198
NM_025415 CKS2  CDC28 protein kinase regulatory subunit 2 1.48 0.0403 0.272589
Cell cycle genes upregulated in PTP1B -/-
Fig. S2. Absence of PTP1B increases expression of cell cycle genes and of the PR target Rankl. (A) Upregulated cell 
cycle genes (top) and upregulated estrogen-responsive genes (bottom) in nulliparous Ptp1b–/– glands compared with wild-
type littermates. (B) Representative images of mammary gland sections stained for Rankl. Scale bars: 50 mm.
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Fig. S3. Absence of PTP1B does not affect plasma levels of pregnancy hormones in mice at estrus and does not alter 
mammary gland involution. (A) Plasma levels of estrogen, progesterone and prolactin in nulliparous mice at estrus as 
assessed by ELISA (the plasma of three mice per group was pooled and analyzed using estradiol and progesterone ELISA 
from DRG Diagnostic and prolactin ELISA from Abcam). (B) Fold changes in Prl-R mRNA as assessed by quantitative 
real-time PCR. Values represent mean ± s.e.m. (n=3). (C) The ratios of pJak2/Jak2 in virgin and pregnant (day 10) mice. 
pJak2 levels were assessed using an ELISA assay (Tyr1007/1008, Invitrogen) and normalized to total Jak2 levels assessed 
by immunoblotting. Values represent mean ± s.e.m. (n=3, *P<0.05 by Student’s t-test). (D) Immunoblots of lysates from 
glands in virgin and pregnancy day 10 mice (Jak2 antibody, Cell Signaling). (E) Representative images of whole-mounts 
of Ptp1b–/– and Ptp1b+/+ mammary glands at involution day 5. Scale bars: 5 mm.
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Table S1. Top 19 affected Gene Ontology terms in Ptp1b–/– versus 
Ptp1b+/+ mammary glands 
 
Gene Ontology term upregulated in Ptp1b–/– Cluster frequency Corrected 
P-value 
Cellular process 244 of 359 genes, 68.0% 4.06E–26 
Cell cycle 50 of 359 genes, 13.9% 3.85E–16 
Cell division 30 of 359 genes, 8.4% 2.96E–15 
Cell cycle phase 35 of 359 genes, 9.7% 4.94E–15 
Cell cycle process 40 of 359 genes, 11.1% 7.08E–15 
M phase 30 of 359 genes, 8.4% 2.50E–14 
Biological regulation 168 of 359 genes, 46.8% 7.51E–14 
M phase of mitotic cell cycle 24 of 359 genes, 6.7% 1.55E–12 
Cellular component organization or 
biogenesis 
85 of 359 genes, 23.7% 2.32E–12 
Cellular component organization 83 of 359 genes, 23.1% 2.34E–12 
Nuclear division 23 of 359 genes, 6.4% 6.14E–12 
Mitosis 23 of 359 genes, 6.4% 6.14E–12 
Mitotic cell cycle 31 of 359 genes, 8.6% 6.45E–12 
Organelle fission 23 of 359 genes, 6.4% 1.98E–11 
Organelle organization 54 of 359 genes, 15.0% 3.02E–11 
Regulation of biological process 157 of 359 genes, 43.7% 3.21E–11 
Cellular component organization at cellular 
level 
68 of 359 genes, 18.9% 4.63E–11 
Cellular component organization or 
biogenesis at cellular level 
69 of 359 genes, 19.2% 1.29E–10 
Metabolic process 159 of 359 genes, 44.3% 9.95E–10 
 
Gene Ontology term downregulated in  
Ptp1b–/– 
Cluster frequency Corrected 
P-value 
Alcohol metabolic process 10 of 62 genes, 16.1% 3.16E–06 
Small molecule metabolic process 19 of 62 genes, 30.6% 3.18E–06 
Glucose metabolic process 7 of 62 genes, 11.3% 5.47E–06 
Carbohydrate metabolic process 10 of 62 genes, 16.1% 1.38E–05 
Hexose metabolic process 7 of 62 genes, 11.3% 1.88E–05 
Cellular carbohydrate metabolic process 9 of 62 genes, 14.5% 2.54E–05 
Monosaccharide metabolic process 7 of 62 genes, 11.3% 6.20E–05 
Cellular process 44 of 62 genes, 71.0% 0.00011 
Carbohydrate transport 5 of 62 genes, 8.1% 0.00059 
Skeletal muscle contraction 3 of 62 genes, 4.8% 0.00104 
Localization 20 of 62 genes, 32.3% 0.00111 
Transport 18 of 62 genes, 29.0% 0.00122 
Striated muscle contraction 4 of 62 genes, 6.5% 0.0013 
Establishment of localization 18 of 62 genes, 29.0% 0.00157 
Biological regulation 33 of 62 genes, 53.2% 0.00245 
Regulation of striated muscle contraction 3 of 62 genes, 4.8% 0.0026 
Metabolic process 33 of 62 genes, 53.2% 0.0038 
Protein homooligomerization 5 of 62 genes, 8.1% 0.00387 
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List of Gene Ontology terms upregulated  and downregulated  in 
Ptp1b–/–  compared  with Ptp1b+/+  glands from nulliparous mice at 
estrus. Terms were obtained from the Process Ontology of 
gene_association.mgi (P<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion and outlook 
 
 
 
 
53 
6. DISCUSSION AND OUTLOOK 
 
In this study we found that PTP1B plays an important role in mammary gland 
alveologenesis and lactogenesis. Using PTP1B knockout mice we determined that: 
a)  PTP1B controls mammary epithelial cell fate: it constrains the number of 
mammary alveolar progenitors in nulliparous mice and restrains alveoli 
formation during early pregnancy. 
b) PTP1B also constrains milk expression during pregnancy.  
 
6.1 Role of PTP1B in cell fate commitment and alveologenesis 
 
Alveologenesis is a developmental program characterized by the expansion and 
differentiation of mammary progenitor cells into cells able to form alveoli. In this 
study we found that loss of PTP1B enhances the number of progenitor cells in 
nulliparous mice. This enhances the pool of cells able to generate alveolar structures 
during pregnancy and, therefore, results in the increased alveolar density observed in 
PTP1B
-/- 
glands during early pregnancy. 
Several factors influence mammary gland alveologensis. We found that lack 
of PTP1B induces the expression of several estrogen-responsive genes in nulliparous 
glands, including progesterone receptor and its downstream target RANK-L. PR plays 
a fundamental role in epithelial cell proliferation and alveolar formation during early 
pregnancy (Lydon 1995; Mulac-Jericevic 2003). Therefore, the precocious alveolar 
development observed in PTP1B
-/-
 glands could be mediated by the overexpression 
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and activation of PR, which is then able to initiate alveologenesis at an earlier time 
point than in the wild-type mammary glands. 
In addition to PR, several transcription factors, like ELF5, GATA3 and 
STAT5, are important for alveolar development. These transcription factors regulate 
differentiation of mammary epithelial stem cells along the luminal epithelial lineage 
(Asselin-Labat 2007; Oakes 2008; Yamaji 2009). STAT5 is a hormonally responsive 
transcription factor that plays a key role in mammary gland alveologenesis and 
lactogenesis (Liu, Robinson et al. 1995; Liu, Robinson et al. 1997). Indeed, STAT5 
increases the number of mammary luminal progenitor cells (Yamaji et al., 2009), 
enhances proliferation of epithelial cells, and promotes alveologenesis (Cui et al., 
2004; Miyoshi et al., 2001). Similar phenotypes were also observed in mammary 
glands lacking PTP1B, suggesting STAT5 as molecular link, in addition to PR, 
between the loss of PTP1B and the precocious alveologenesis. 
 The findings that PTP1B depletion induces the expression of PR and 
the activation of STAT5 raise the possibility that they act in a common signaling 
pathway to regulate alveologenesis. Cui et al. showed that STAT5 required the 
hormonal stimulation of estrogen and progesterone to induce proliferation of 
epithelial cells in the mammary gland (Cui 2004). Furthermore, PR regulates 
expression of PrlR, a key regulator of STAT5 phosphorylation and activation 
(Ormandy 1992). These observations further suggest a molecular link between PR and 
STAT5 in PTP1B
-/-
 mice.  
In vitro studies have demonstrated that PTP1B can directly dephosphorylate 
STAT5 (Aoki 2002), opening the hypothesis that PTP1B may downregulate 
progesterone receptor expression and inhibit STAT5 activation in two independent 
pathways. 
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In conclusion, our studies suggest a role for PTP1B as a temporal regulator of 
mammary gland development, which downregulates the progesterone and STAT5 
pathway(s) in order to prevent the inappropriate onset of alveologenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7 Model of the mechanism of action of PTP1B in the control of mammary 
epithelial cell fate. 
 
6.2 Role of PTP1B in lactogenesis 
 
Our studies also support a role of PTP1B in lactogenesis. We showed that PTP1B 
deletion induces precocious secretion of milk proteins during late pregnancy, due to 
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an enhanced STAT5 phosphorylation and activation. This study suggests a role for 
PTP1B in the prevention of an inappropriate onset of lactogenesis during pregnancy. 
 
6.3 Concluding remarks and future directions 
 
Mammary gland development and differentiation is a complex mechanism regulated 
by several different pathways (Brisken 2010, Henninghausen 2005). Therefore, 
PTP1B may act via further pathways to constrain mammary gland alveologenesis and 
lactogenesis. 
The increased activation of the ER and PR pathways seen in PTP1B
-/-
 glands 
could be mediated by higher levels of hormones in the blood. However, we found no 
difference between estrogen, progesterone and prolactin levels in plasmas of PTP1B 
knockout and wild-type nulliparous mice. These results suggest that PTP1B 
constrains mammary alveologenesis by regulating the hormones responsiveness of the 
epithelial cells to normal circulating hormone levels. 
Several studies showed that insulin, IGF 1 and IGF 2 are important in 
mammary gland morphogenesis (Kleinberg, Feldman et al. 2000; Brisken, Ayyannan 
et al. 2002; Hovey, Harris et al. 2003; Berlato and Doppler 2009). Since PTP1B is a 
well-known metabolic regulator that dephosphorylates the insulin and leptin pathways 
in other organs (Elchebly 1999, Klaman 2000), we cannot exclude that PTP1B may 
also act via the insulin pathways to constrain mammary gland morphogenesis. A 
hypothesis that warrants further investigations. 
The mammary stem cell hierarchy is tightly regulated to guarantee the correct 
formation of a functional mammary gland. Deregulation in the mammary stem cell 
hierarchy may lead to breast cancer development. Therefore, the finding that PTP1B 
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constrains the commitment of a primitive stem/progenitor cells to more differentiated 
progenitor cells open the hypothesis of a link between the role of PTP1B in mammary 
gland development and the involvement of PTP1B in tumorigenesis. 
Epidemiological studies have shown that early menarche, late menopause and 
late age of first pregnancy are all risk factors for developing sporadic breast cancer 
(Kampert, Whittemore et al. 1988). The hormonal milieu and breast development 
cycles, probably through changes in the differentiation state of breast stem/progenitor 
cells, affect the susceptibility of the breast to oncogenic transformation. Our findings 
that PTP1B deletion induces precocious differentiation of the mammary gland raise 
the possibility that the cells of origin of HER2/Neu-evoked mammary tumors may be 
decreased in PTP1B
-/-
 mice. This possibility would explain why deletion of PTP1B 
delays or prevents mammary tumor formation in MMTV-NeuNT and MMTV-NDL1 
mice (Balavenkatraman et al., 2011; Bentires-Alj and Neel, 2007; Julien et al., 2007). 
This possibility merits further investigations. 
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8. ABBREVIATIONS 
 
  
CD24 heat stable antigen 
CD29 b-integrin 
CD49f  a6-integrin 
CD61  b3-integrin 
ER estrogen receptor 
HER2 epidermal growth factor receptor 2 
IGF 1 insulin-like growth factor 1  
IGF 2 insulin-like growth factor 2 
IR insulin receptor  
JAK2 janus kinase 2 
MaSC mammary stem cell 
MEC mammary epithelial cells  
MRU mammary repopulating units  
PR progesterone receptor 
PrlR prolactin receptor 
PrlR Prolactin 
PTK protein-tyrosine kinases  
PTP protein tyrosine-phosphatases  
PTP1B protein-tyrosine phosphatase 1B 
RANK-L activator of nuclear factor kB (NF-kB) ligand 
ROS reactive oxygen species  
STAT5 signal transducers and activators of transcription 5 
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